From the Journals

Psilocybin Beats Nicotine Patch in Smoking Trial

A single psilocybin dose outperforms standard nicotine replacement, opening a new front in one of medicine’s most intractable problems.

Share

A recent pilot study published in JAMA Network Open found that a single high dose of psilocybin combined with cognitive behavioral therapy significantly increased the odds of prolonged smoking abstinence at 6 months compared to nicotine patches and CBT. Conducted at Johns Hopkins Bayview Medical Center from January 2015 to May 2023, the trial involved 82 adult smokers with prior cessation attempts. Results indicated that 41% in the psilocybin group maintained abstinence compared to only 10% in the nicotine patch group. The study supports the potential of psilocybin for tobacco use disorder treatment.

Original Source(s)

Psilocybin Beats Nicotine Patch in Smoking Trial

A single psilocybin dose outperforms standard nicotine replacement, opening a new front in one of medicine’s most intractable problems.

  • by Kerri Miller

  • March 10, 2026

  • 6 min

Related Content

Singing Program Feasible After Pulmonary Rehabilitation

Study finds 12-week singing intervention feasible following pulmonary rehabilitation, supporting larger trial.

COPD Clinical Trials at Temple Lung Center

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity, and many patients continue to experience symptoms despite optimal therapy. As one of the world’s largest and most experienced COPD research programs, the Temple Lung Center offers access to clinical trials evaluating new pharmacologic, device-based, and comprehensive treatment approaches.

  • by

  • February 19, 2026

  • 2 min
Chronic Cough Despite Normal Workup

Researchers describe diagnostic evaluation and management considerations when standard testing fails to identify the cause of persistent cough.